Previous 10 | Next 10 |
home / stock / frx:cc / frx:cc news
~ Under the Terms of the Previously Announced Investment Agreement, $5 Million Already Funded Upon Initial Closing, Which Occurred on August 19, 2022, and $20 Million to be Funded Upon FDA Approval of PEDMARK® Which Occurred on September 20, 2022 ~ ~ Fennec Has the Pote...
~ PEDMARK ® is the First and Only FDA-Approved Therapy Indicated to Reduce the Risk of Ototoxicity Associated with Cisplatin in Pediatric Patients with Localized, Non-Metastatic Solid Tumors ~ RESEARCH TRIANGLE PARK, N.C., Sept. 21, 2022 (GLOBE NEWSWIRE) -- Fennec Pharmac...
~ Under the Terms of the Investment Agreement, $5 Million to be Funded on initial closing and $20 Million to be Funded Upon Potential FDA Approval of PEDMARK TM ~ ~ Fennec Has the Potential to Access an Additional $20 Million Prior to December 31, 2023 ~ RESEAR...
~ PEDMARK TM FDA Prescription Drug User Fee Act (PDUFA) Target Action Date Set for September 23, 2022 ~ ~ Commercial Team Built Out In Anticipation of U.S. Launch of PEDMARK TM ~ ~ Recently Announced Up to $45 Million in Funding from Petrichor...
~ Under the Terms of the Investment Agreement, $5 Million to be Funded on initial closing and $20 Million to be Funded Upon Potential FDA Approval of PEDMARK TM ~ ~ Fennec Has the Potential to Access an Additional $20 Million Prior to December 31, 2023 ~ ~ Fu...
RESEARCH TRIANGLE PARK, N.C., June 14, 2022 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (the “Company”) (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the management proxy circular dated April 20, 2022 (the “Circular”) for the Annual Gene...
RESEARCH TRIANGLE PARK, N.C., May 23, 2022 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARK TM (a unique formulation of sodium thiosulfate) for the prevention of platinum-induced ototoxicity...
~ FDA Prescription Drug User Fee Act (PDUFA) Target Action Date Set for September 23, 2022 ~ ~ If Approved by the FDA, PEDMARK TM Stands to Be the First Therapy for the Prevention of Cisplatin-Induced Hearing Loss in Children ~ ~ Company Has Approximately $18.3...
RESEARCH TRIANGLE PARK, N.C., , April 27, 2022 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company’s resubmitted New Drug...
RESEARCH TRIANGLE PARK, N.C., March 25, 2022 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARK™ (a unique formulation of sodium thiosulfate) for the prevention of platinum-induced ot...
News, Short Squeeze, Breakout and More Instantly...
Fennec Pharmaceuticals Inc. Company Name:
FRX:CC Stock Symbol:
TSXC Market:
Fennec Pharmaceuticals Inc. Website:
A look at the top 10 most actives in Canada Toronto-Dominion Bank (The) (TD) fell 0.9% to $75.22 on volume of 16,671,142 shares Bank of Nova Scotia (The) (BNS) fell 0.7% to $61.6 on volume of 10,953,303 shares TC Energy Corporation (TRP) fell 1.1% to $51.64 on volume of 10,661,745 shares ...
A look at the top 10 most actives in Canada Fission Uranium Corp. (FCU) rose 5.9% to $1.25 on volume of 21,445,305 shares iShares S&P/TSX 60 Index ETF (XIU) rose 1.4% to $33.6 on volume of 18,474,835 shares TC Energy Corporation (TRP) rose 1.1% to $52.16 on volume of 14,728,718 shares...
RESEARCH TRIANGLE PARK, N.C., July 01, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that Adrian Haigh has departed from his position as Fennec’s Chief Operating Officer as of June 30, 202...